2019 - Distinguished Fellows of the American Association of Immunologists (AAI)
2016 - American Association of Immunologists Lifetime Achievement Award
2016 - AAI Lifetime Achievement Award, American Association of Immunologists
The scientist’s investigation covers issues in Immunology, Antigen, Immune system, Epitope and T cell. Her Immunology study integrates concerns from other disciplines, such as Cancer research and Pancreatic cancer. Her Antigen study incorporates themes from Cancer, Cytotoxic T cell, Tumor antigen and Antibody.
Olivera J. Finn has researched Cancer in several fields, including Translational research and Computational biology. Her work carried out in the field of Epitope brings together such families of science as Molecular biology, Mucin, Monoclonal antibody and Adenocarcinoma. The various areas that Olivera J. Finn examines in her T cell study include Acquired immune system and Immunogenicity.
Immunology, Antigen, Cancer, Immune system and MUC1 are her primary areas of study. Her studies in Immunology integrate themes in fields like Cytotoxic T cell and Cancer research. Her Cytotoxic T cell research incorporates themes from CD8 and Major histocompatibility complex.
Her study explores the link between Antigen and topics such as Molecular biology that cross with problems in CTL*. Her Cancer study deals with the bigger picture of Internal medicine. Her Immune system study combines topics from a wide range of disciplines, such as Adjuvant, Disease and Vaccination.
Her scientific interests lie mostly in Immunology, Cancer, Antigen, Immune system and MUC1. Cancer vaccine, T cell and Vaccination are among the areas of Immunology where Olivera J. Finn concentrates her study. Her work on Immunotherapy and Cancer prevention is typically connected to Myeloid-derived Suppressor Cell as part of general Cancer study, connecting several disciplines of science.
Her Antigen research incorporates elements of Antibody, Gene, Tumor antigen and Virology. Her research in the fields of Immunosurveillance, Immunity and Autoimmunity overlaps with other disciplines such as Glycopeptide. Her study in MUC1 is interdisciplinary in nature, drawing from both Gastroenterology, Metastasis and Disease.
Olivera J. Finn focuses on Antigen, Cancer, Immune system, Immunosurveillance and Immunology. Her Antigen research is multidisciplinary, incorporating perspectives in Antibody and Tumor antigen. Her Cancer study often links to related topics such as Cancer research.
Her studies deal with areas such as Virus and Gene as well as Immune system. Her work deals with themes such as T cell and Pancreatic cancer, which intersect with Immunosurveillance. While the research belongs to areas of Immunology, Olivera J. Finn spends her time largely on the problem of Cancer prevention, intersecting her research to questions surrounding Normal tissue and Disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever;Martin A. Cheever;James P. Allison;Andrea S. Ferris;Olivera J. Finn.
Clinical Cancer Research (2009)
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
Jan Schmielau;Olivera J. Finn.
Cancer Research (2001)
Cancer vaccines: between the idea and the reality.
Olivera J. Finn.
Nature Reviews Immunology (2003)
Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells
Donna L. Barnd;Michael S. Lan;Richard S. Metzgar;Olivera J. Finn.
Proceedings of the National Academy of Sciences of the United States of America (1989)
Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
Keith R. Jerome;Donna L. Barnd;Katharine M. Bendt;Cinda M. Boyer.
Cancer Research (1991)
Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients
Y Kotera;J D Fontenot;G Pecher;R S Metzgar.
Cancer Research (1994)
MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines
Olivera J. Finn;Keith R. Jerome;Robert A. Henderson;Gabriele Pecher.
Immunological Reviews (1995)
A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma
James S. Goydos;Elaine Elder;Theresa L. Whiteside;Olivera J. Finn.
Journal of Surgical Research (1996)
MCF7 Side Population Cells with Characteristics of Cancer Stem/Progenitor Cells Express the Tumor Antigen MUC1
Katja Engelmann;Hongmei Shen;Olivera J. Finn.
Cancer Research (2008)
Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.
C G Ioannides;B Fisk;K R Jerome;T Irimura.
Journal of Immunology (1993)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: